inclusion criteria: * male or female, aged ≥18 years of age; * laboratory confirmed infection with covid-19 virus by an fda-authorized sars-cov-2 rt-pcr; * able and willing to give written informed consent. * willing to keep an electronic diary from study day 1 to study day 13 (± 1 day) and study day 15 (± 1 day) to study day 28 (± 1 day) * willing to have daily phone or videoconferences with study team personnel from study day 1 to day 13 (± 1 day) and day 28 * at least one of the following clinical symptoms of covid-19 infection within the 4 days prior to and inclusive of the day of screening: 1. respiratory rate ≥ 24/min 2. new cough or shortness of breath that has presented within the last 4 days 3. fever - temperature 37.7°c \[oral or skin surface\] * must agree not to enroll in another study of an investigational agent prior to completion of day 28 of the study. * able to take arakoda or kodatef according to prescribing information * have been symptomatic no longer than 7 days when the first dose of study medication is administered. * if female, agree to use an acceptable method of birth control from the time of consent through 56 days after the last dose of study drug.

inclusion criteria: * male or female, aged ≥18 years of age; * laboratory confirmed infection with covid-19 virus by an fda-authorized sars-cov-2 rt-pcr; * able and willing to give written informed consent. * willing to keep an electronic diary from study day 1 to study day 13 (± 1 day) and study day 15 (± 1 day) to study day 28 (± 1 day) * willing to have daily phone or videoconferences with study team personnel from study day 1 to day 13 (± 1 day) and day 28 * at least one of the following clinical symptoms of covid-19 infection within the 4 days prior to and inclusive of the day of screening: 1. respiratory rate ≥ 24/min 2. new cough or shortness of breath that has presented within the last 4 days 3. fever - temperature 37.7°c \[oral or skin surface\] * must agree not to enroll in another study of an investigational agent prior to completion of day 28 of the study. * able to take arakoda or kodatef according to prescribing information * have been symptomatic no longer than 7 days when the first dose of study medication is administered. * if female, agree to use an acceptable method of birth control from the time of consent through 56 days after the last dose of study drug.

inclusion criteria: male or female, aged ≥18 years of age; laboratory confirmed infection with covid-19 virus by an fda-authorized sars-cov-2 rt-pcr; able and willing to give written informed consent. willing to keep an electronic diary from study day 1 to study day 13 (± 1 day) and study day 15 (± 1 day) to study day 28 (± 1 day) willing to have daily phone or videoconferences with study team personnel from study day 1 to day 13 (± 1 day) and day 28 at least one of the following clinical symptoms of covid-19 infection within the 4 days prior to and inclusive of the day of screening: respiratory rate ≥ 24/min new cough or shortness of breath that has presented within the last 4 days fever - temperature 37.7°c [oral or skin surface] must agree not to enroll in another study of an investigational agent prior to completion of day 28 of the study. able to take arakoda or kodatef according to prescribing information have been symptomatic no longer than 7 days when the first dose of study medication is administered. if female, agree to use an acceptable method of birth control from the time of consent through 56 days after the last dose of study drug.

inclusion criteria: male or female, aged ≥18 years of age; laboratory confirmed infection with covid-19 virus by an fda-authorized sars-cov-2 rt-pcr; able and willing to give written informed consent. willing to keep an electronic diary from study day 1 to study day 13 (± 1 day) and study day 15 (± 1 day) to study day 28 (± 1 day) willing to have daily phone or videoconferences with study team personnel from study day 1 to day 13 (± 1 day) and day 28 at least one of the following clinical symptoms of covid-19 infection within the 4 days prior to and inclusive of the day of screening: respiratory rate ≥ 24/min new cough or shortness of breath that has presented within the last 4 days fever - temperature 37.7°c [oral or skin surface] must agree not to enroll in another study of an investigational agent prior to completion of day 28 of the study. able to take arakoda or kodatef according to prescribing information have been symptomatic no longer than 7 days when the first dose of study medication is administered. if female, agree to use an acceptable method of birth control from the time of consent through 56 days after the last dose of study drug.

inclusion criteria: - male or female, aged ≥18 years of age; - laboratory confirmed infection with covid-19 virus by an fda-authorized sars-cov-2 rt-pcr; - able and willing to give written informed consent. - willing to keep an electronic diary from study day 1 to study day 13 (± 1 day) and study day 15 (± 1 day) to study day 28 (± 1 day) - willing to have daily phone or videoconferences with study team personnel from study day 1 to day 13 (± 1 day) and day 28 - at least one of the following clinical symptoms of covid-19 infection within the 4 days prior to and inclusive of the day of screening: 1. respiratory rate ≥ 24/min 2. new cough or shortness of breath that has presented within the last 4 days 3. fever - temperature 37.7°c [oral or skin surface] - must agree not to enroll in another study of an investigational agent prior to completion of day 28 of the study. - able to take arakoda or kodatef according to prescribing information - have been symptomatic no longer than 7 days when the first dose of study medication is administered. - if female, agree to use an acceptable method of birth control from the time of consent through 56 days after the last dose of study drug.

inclusion criteria: - male or female, aged ≥18 years of age; - laboratory confirmed infection with covid-19 virus by an fda-authorized sars-cov-2 rt-pcr; - able and willing to give written informed consent. - willing to keep an electronic diary from study day 1 to study day 13 (± 1 day) and study day 15 (± 1 day) to study day 28 (± 1 day) - willing to have daily phone or videoconferences with study team personnel from study day 1 to day 13 (± 1 day) and day 28 - at least one of the following clinical symptoms of covid-19 infection within the 4 days prior to and inclusive of the day of screening: 1. respiratory rate ≥ 24/min 2. new cough or shortness of breath that has presented within the last 4 days 3. fever - temperature 37.7°c [oral or skin surface] - must agree not to enroll in another study of an investigational agent prior to completion of day 28 of the study. - able to take arakoda or kodatef according to prescribing information - have been symptomatic no longer than 7 days when the first dose of study medication is administered. - if female, agree to use an acceptable method of birth control from the time of consent through 56 days after the last dose of study drug.

inclusion criteria: - male or female, aged ≥18 years of age; - laboratory confirmed infection with covid-19 virus by an fda-authorized sars-cov-2 rt-pcr; - able and willing to give written informed consent. - willing to keep an electronic diary from study day 1 to study day 13 (± 1 day) and study day 15 (± 1 day) to study day 28 (± 1 day) - willing to have daily phone or videoconferences with study team personnel from study day 1 to day 13 (± 1 day) and day 28 - at least one of the following clinical symptoms of covid-19 infection within the 4 days prior to and inclusive of the day of screening: 1. respiratory rate ≥ 24/min 2. new cough or shortness of breath that has presented within the last 4 days 3. fever - temperature 37.7°c [oral or skin surface] - must agree not to enroll in another study of an investigational agent prior to completion of day 28 of the study. - able to take arakoda or kodatef according to prescribing information - have been symptomatic no longer than 5 days when the first dose of study medication is administered. - if female, agree to use an acceptable method of birth control from the time of consent through 56 days after the last dose of study drug.

inclusion criteria: - male or female, aged ≥18 years of age; - laboratory confirmed infection with covid-19 virus by an fda-authorized sars-cov-2 rt-pcr; - able and willing to give written informed consent. - willing to keep an electronic diary from study day 1 to study day 13 (± 1 day) and study day 15 (± 1 day) to study day 28 (± 1 day) - willing to have daily phone or videoconferences with study team personnel from study day 1 to day 13 (± 1 day) and day 28 - at least one of the following clinical symptoms of covid-19 infection within the 4 days prior to and inclusive of the day of screening: 1. respiratory rate ≥ 24/min 2. new cough or shortness of breath that has presented within the last 4 days 3. fever - temperature 37.7°c [oral or skin surface] - must agree not to enroll in another study of an investigational agent prior to completion of day 28 of the study. - able to take arakoda or kodatef according to prescribing information - have been symptomatic no longer than 5 days when the first dose of study medication is administered. - if female, agree to use an acceptable method of birth control from the time of consent through 56 days after the last dose of study drug.

inclusion criteria: - male or female, aged ≥18 years of age; - laboratory confirmed infection with covid-19 virus by an fda-authorized sars-cov-2 rt-pcr; - able and willing to give written informed consent. - willing to keep an electronic diary from study day 1 to day 12 [± 1 day] and have daily phone or videoconferences with study team personnel. - at least one of the following clinical symptoms of covid-19 infection within the 4 days prior to and inclusive of the day of screening: 1. respiratory rate ≥ 24/min 2. new cough or shortness of breath that has presented within the last 4 days 3. fever - temperature 37.7°c [oral or skin surface] - must agree not to enroll in another study of an investigational agent prior to completion of day 28 of the study. - able to take arakoda or kodatef according to prescribing information - have been symptomatic no longer than 5 days when the first dose of study medication is administered. - if female, agree to use an acceptable method of birth control from the time of consent through 56 days after the last dose of study drug.

inclusion criteria: - male or female, aged ≥18 years of age; - laboratory confirmed infection with covid-19 virus by an fda-authorized sars-cov-2 rt-pcr; - able and willing to give written informed consent. - willing to keep an electronic diary from study day 1 to day 12 [± 1 day] and have daily phone or videoconferences with study team personnel. - at least one of the following clinical symptoms of covid-19 infection within the 4 days prior to and inclusive of the day of screening: 1. respiratory rate ≥ 24/min 2. new cough or shortness of breath that has presented within the last 4 days 3. fever - temperature 37.7°c [oral or skin surface] - must agree not to enroll in another study of an investigational agent prior to completion of day 28 of the study. - able to take arakoda or kodatef according to prescribing information - have been symptomatic no longer than 5 days when the first dose of study medication is administered. - if female, agree to use an acceptable method of birth control from the time of consent through 56 days after the last dose of study drug.